Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Endovascular Technologies, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Endovascular Technologies, Inc.: Expects to begin prospective Phase II clinical trials of its Aortoiliac EGS system, which is designed to treat aneurysms in which one iliac artery is unsuitable for endovascular attachment of an implant. The planned 20-site study, for which an investigational device exemption application recently was approved by FDA, will compare mortality, complications, and length of hospital stay among patients treated with the Aortoiliac EGS and those receiving conventional treatment...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel